Clinical trial
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
NCT00070759 · National Eye Institute (NEI), NIH · Completed
Key facts
| NCT number | NCT00070759 |
|---|---|
| Title | Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis |
| Official title | Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study |
| Lead sponsor | National Eye Institute (NEI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Uveitis |
| Intervention type | Drug |
| Interventions | Daclizumab |
| Enrollment | 6 |
| Start date | Oct 6, 2003 |
| Completion | Oct 2, 2006 |
| First posted | Oct 8, 2003 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: